


## WHAT IS CLAIMED IS

1. A method of inhibiting human stearoyl-CoA desaturase (hSCD) activity comprising contacting a source of hSCD with a compound of formula (I):



wherein:

x and y are each independently 1, 2 or 3;

W is  $-N(R^1)C(O)-$ ,  $-C(O)N(R^1)-$ ,  $-OC(O)N(R^1)-$ ,  $-N(R^1)C(O)N(R^1)-$ ,  $-O-$ ,  $-N(R^1)-$ ,  $-S(O)_t-$  (where t is 0, 1 or 2),  $-N(R^1)S(O)_2-$ ,  $-S(O)_2N(R^1)-$ ,  $-C(O)-$ ,  $-OS(O)_2N(R^1)-$ ,  $-OC(O)-$ ,  $-C(O)O-$  or  $-N(R^1)C(O)O-$ ;

V is  $-C(O)-$ ,  $-C(O)O-$ ,  $-C(S)-$ ,  $-C(O)N(R^1)-$ ,  $-S(O)_2-$ ,  $-S(O)_2N(R^1)-$  or  $-C(R^{10})H-$ ;

G, J, L and M are each independently selected from  $-N=$  or  $-C(R^4)=$ ; provided that at least two of G, J, L and M are  $-N=$ , and provided that when G and J are both  $-C(R^4)=$ , L and M can not both be  $-N=$ , and when L and M are both  $-C(R^4)=$ , G and J can not both be  $-N=$ ;

each  $R^1$  is independently selected from the group consisting of hydrogen,  $C_1-C_{12}$ alkyl,  $C_2-C_{12}$ hydroxyalkyl,  $C_4-C_{12}$ cycloalkylalkyl and  $C_7-C_{19}$ aralkyl;

$R^2$  is selected from the group consisting of  $C_1-C_{12}$ alkyl,  $C_2-C_{12}$ alkenyl,  $C_2-C_{12}$ hydroxyalkyl,  $C_2-C_{12}$ hydroxyalkenyl,  $C_2-C_{12}$ alkoxyalkyl,  $C_3-C_{12}$ cycloalkyl,  $C_4-C_{12}$ cycloalkylalkyl, aryl,  $C_7-C_{19}$ aralkyl,  $C_3-C_{12}$ heterocyclyl,  $C_3-C_{12}$ heterocyclylalkyl,  $C_1-C_{12}$ heteroaryl, and  $C_3-C_{12}$ heteroarylalkyl;

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

$R^3$  is selected from the group consisting of  $C_1-C_{12}$ alkyl,  $C_2-C_{12}$ alkenyl,  $C_2-C_{12}$ hydroxyalkyl,  $C_2-C_{12}$ hydroxyalkenyl,  $C_2-C_{12}$ alkoxyalkyl,  $C_3-C_{12}$ cycloalkyl,  $C_4-C_{12}$ cycloalkylalkyl, aryl,  $C_7-C_{19}$ aralkyl,  $C_3-C_{12}$ heterocyclyl,  $C_3-C_{12}$ heterocyclylalkyl,  $C_1-C_{12}$ heteroaryl and  $C_3-C_{12}$ heteroarylalkyl;

or  $R^3$  is a multi-ring structure having 2 to 4 rings wherein the rings are

independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

each R<sup>4</sup> is independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>9</sup>)<sub>2</sub>;

each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

or R<sup>5</sup> and R<sup>5a</sup> together, or R<sup>6</sup> and R<sup>6a</sup> together, or R<sup>7</sup> and R<sup>7a</sup> together, or R<sup>8</sup> and R<sup>8a</sup> together are an oxo group, provided that when V is -C(O)-, R<sup>6</sup> and R<sup>6a</sup> together or R<sup>8</sup> and R<sup>8a</sup> together do not form an oxo group, while the remaining R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> are each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;


or one of R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, and R<sup>6a</sup> together with one of R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> form an alkylene bridge, while the remaining R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, and R<sup>8a</sup> are each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

R<sup>10</sup> is hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl; and

each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

2. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I):



wherein:

x and y are each independently 1, 2 or 3;

W is -N(R<sup>1</sup>)C(O)-, -C(O)N(R<sup>1</sup>)-, -OC(O)N(R<sup>1</sup>)-, -N(R<sup>1</sup>)C(O)N(R<sup>1</sup>)-, -O-, -N(R<sup>1</sup>)-, -S(O)<sub>t</sub>- (where t is 0, 1 or 2), -N(R<sup>1</sup>)S(O)<sub>t</sub>-, -S(O)<sub>2</sub>N(R<sup>1</sup>)-, -C(O)-, -OS(O)<sub>2</sub>N(R<sup>1</sup>)-, -OC(O)-, -C(O)O- or -N(R<sup>1</sup>)C(O)O-;

V is -C(O)-, -C(O)O-, -C(S)-, -C(O)N(R<sup>1</sup>)-, -S(O)<sub>2</sub>-, -S(O)<sub>2</sub>N(R<sup>1</sup>)- or -C(R<sup>10</sup>)H-;

G, J, L and M are each independently selected from -N= or -C(R<sup>4</sup>)=; provided that at least two of G, J, L and M are -N=, and provided that when G and J are both -C(R<sup>4</sup>)=, L and M can not both be -N=, and when L and M are both -C(R<sup>4</sup>)=, G and J can not both be -N=;

each R<sup>1</sup> is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>19</sub>aralkyl;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>2</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl, and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

or R<sup>2</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R<sup>3</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>2</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

or R<sup>3</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

each R<sup>4</sup> is independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>9</sup>)<sub>2</sub>;

each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;


or R<sup>5</sup> and R<sup>5a</sup> together, or R<sup>6</sup> and R<sup>6a</sup> together, or R<sup>7</sup> and R<sup>7a</sup> together, or R<sup>8</sup> and R<sup>8a</sup> together are an oxo group, provided that when V is -C(O)-, R<sup>6</sup> and R<sup>6a</sup> together or R<sup>8</sup> and R<sup>8a</sup> together do not form an oxo group, while the remaining R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> are each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

or one of R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, and R<sup>6a</sup> together with one of R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> form an alkylene bridge, while the remaining R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, and R<sup>8a</sup> are each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

R<sup>10</sup> is hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl; and

each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl; a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

3. The method of Claim 2 wherein the mammal is a human.
4. The method of Claim 3 wherein the disease or condition is selected from the group consisting of fatty liver, non-alcoholic steatohepatitis, Type II diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia and metabolic syndrome and any combination of these.
5. The method of Claim 4 wherein the disease or condition is Type II diabetes.
6. The method of Claim 4 wherein the disease or condition is obesity.
7. The method of Claim 4 wherein the disease or condition is metabolic syndrome.
8. The method of Claim 4 wherein the disease or condition is fatty liver.
9. The method of Claim 4 wherein the disease or condition is non-alcoholic steatohepatitis.
10. A compound of formula (II):



wherein:

x and y are each independently 1, 2 or 3;

W is -N(R<sup>1</sup>)C(O)-, -C(O)N(R<sup>1</sup>)-, -OC(O)N(R<sup>1</sup>)-, -N(R<sup>1</sup>)C(O)N(R<sup>1</sup>)-, -O-,

-N(R<sup>1</sup>)-, -S(O)<sub>t</sub>- (where t is 0, 1 or 2), -N(R<sup>1</sup>)S(O)<sub>2</sub>-, -S(O)<sub>2</sub>N(R<sup>1</sup>)-, -C(O)-, -OS(O)<sub>2</sub>N(R<sup>1</sup>)-, -OC(O)-, -C(O)O- or -N(R<sup>1</sup>)C(Ö)O-;  
 V is -C(O)-, -C(O)O-, -C(S)-, -C(O)N(R<sup>1</sup>)-, -S(O)<sub>2</sub>-, -S(O)<sub>2</sub>N(R<sup>1</sup>)- or  
 -C(R<sup>10</sup>)H-;

J and M are each independently selected from -N= or -C(R<sup>4</sup>)=; each R<sup>1</sup> is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>19</sub>aralkyl; R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>2</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocycl, C<sub>3</sub>-C<sub>12</sub>heterocyclalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl, and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

or R<sup>2</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocycl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R<sup>3</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>2</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocycl, C<sub>3</sub>-C<sub>12</sub>heterocyclalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

or R<sup>3</sup> is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocycl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

each R<sup>4</sup> is independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>9</sup>)<sub>2</sub>;

each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

or R<sup>5</sup> and R<sup>5a</sup> together, or R<sup>6</sup> and R<sup>6a</sup> together, or R<sup>7</sup> and R<sup>7a</sup> together, or R<sup>8</sup> and R<sup>8a</sup> together are an oxo group, provided that when V is -C(O)-, R<sup>6</sup> and R<sup>6a</sup> together or R<sup>8</sup> and R<sup>8a</sup> together do not form an oxo group, while the remaining R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> are each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

or one of R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, and R<sup>6a</sup> together with one of R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> form an alkylene bridge, while the remaining R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, and R<sup>8a</sup> are each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

R<sup>10</sup> is hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl; and

each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

11. The compound of Claim 10 wherein:

x and y are each independently 1, 2 or 3;

W is -N(R<sup>1</sup>)C(O)-, -C(O)N(R<sup>1</sup>)-, -OC(O)N(R<sup>1</sup>)-, -N(R<sup>1</sup>)C(O)N(R<sup>1</sup>)-, -O-, -N(R<sup>1</sup>)-, -S(O)<sub>t</sub>- (where t is 0, 1 or 2), -N(R<sup>1</sup>)S(O)<sub>2</sub>-, -S(O)<sub>2</sub>N(R<sup>1</sup>)-, -C(O)-, -OS(O)<sub>2</sub>N(R<sup>1</sup>)-, -OC(O)-, -C(O)O- or -N(R<sup>1</sup>)C(O)O-;

V is -C(O)-, -C(O)O-, -C(S)-, -C(O)N(R<sup>1</sup>)-, -S(O)<sub>2</sub>-, -S(O)<sub>2</sub>N(R<sup>1</sup>)- or -C(R<sup>10</sup>)H-;

J and M are each -C(R<sup>4</sup>)=;

each R<sup>1</sup> is independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl and C<sub>7</sub>-C<sub>19</sub>aralkyl;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>2</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocycl, C<sub>3</sub>-C<sub>12</sub>heterocyclalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl, and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>3</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>2</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocycl, C<sub>3</sub>-C<sub>12</sub>heterocyclalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

each R<sup>4</sup> is independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>9</sup>)<sub>2</sub>;

each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

or R<sup>5</sup> and R<sup>5a</sup> together, or R<sup>6</sup> and R<sup>6a</sup> together, or R<sup>7</sup> and R<sup>7a</sup> together, or R<sup>8</sup> and R<sup>8a</sup> together are an oxo group, provided that when V is -C(O)-, R<sup>6</sup> and R<sup>6a</sup> together or R<sup>8</sup> and R<sup>8a</sup> together do not form an oxo group, while the remaining R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> are each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

or one of R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, and R<sup>6a</sup> together with one of R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> form an alkylene bridge, while the remaining R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup>, and R<sup>8a</sup> are each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl; and

each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl.

12. The compound of Claim 11 wherein:

x and y are each independently 1, 2 or 3;

W is -N(R<sup>1</sup>)C(O)-;

V is -C(O)-;

J and M are each -C(R<sup>4</sup>)=;

R<sup>1</sup> is selected from the group consisting of hydrogen or C<sub>1</sub>-C<sub>12</sub>alkyl;

each R<sup>4</sup> is independently selected from hydrogen, fluoro, chloro, methyl,

methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>9</sup>)<sub>2</sub>;

each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is independently selected from  
hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl; and

each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl.

13. The compound of Claim 12 wherein:

x and y are each 1;

each R<sup>4</sup> is hydrogen; and

R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> are each hydrogen.

14. The compound of Claim 13 wherein:

R<sup>3</sup> is aryl optionally substituted by one or more substituents selected  
from the group consisting of halo, cyano, nitro, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl,  
C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, -N(R<sup>12</sup>)<sub>2</sub>, -OC(O)R<sup>12</sup>, -C(O)OR<sup>12</sup>, -S(O)<sub>2</sub>N(R<sup>12</sup>)<sub>2</sub>,  
cycloalkyl, heterocyclyl, heteroaryl and heteroaryl(cycloalkyl; and

each R<sup>12</sup> is independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl,  
C<sub>3</sub>-C<sub>6</sub>cycloalkyl, aryl or aralkyl.

15. The compound of Claim 14 wherein:

R<sup>2</sup> is C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl,  
C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, C<sub>7</sub>-C<sub>19</sub>aralkyl,  
C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl or C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl; and

R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected  
from halo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy.

16. The compound of Claim 15 wherein R<sup>2</sup> is C<sub>7</sub>-C<sub>12</sub>aralkyl optionally  
substituted by one or more substituents selected from halo or C<sub>1</sub>-C<sub>6</sub>trihaloalkyl.

17. The compound of Claim 16 selected from the group consisting of the following:

5-[4-(2-Trifluoromethyl-benzoyl)-piperazin-1-yl]-pyrimidine-2-carboxylic acid phenethylamide;  
5-[4-(2-Trifluoromethyl-benzoyl)-piperazin-1-yl]-pyrimidine-2-carboxylic acid (3-phenylpropyl)-amide; and  
5-[4-(2-Trifluoromethyl-benzoyl)-piperazin-1-yl]-pyrimidine-2-carboxylic acid benzylamide.

18. The compound of Claim 15 wherein R<sup>2</sup> is C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl or C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl.

19. The compound of Claim 18, namely, 5-[4-(2-Trifluoromethyl-benzoyl)-piperazin-1-yl]-pyrimidine-2-carboxylic acid hexylamide.

20. The compound of Claim 11 wherein:

x and y are each independently 1, 2 or 3;

W is -C(O)N(R<sup>1</sup>)-;

V is -C(O)-;

J and M are each -C(R<sup>4</sup>)=;

R<sup>1</sup> is selected from the group consisting of hydrogen or C<sub>1</sub>-C<sub>12</sub>alkyl;

each R<sup>4</sup> is independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>9</sup>)<sub>2</sub>;

each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl; and

each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl.

21. The compound of Claim 11 wherein:

x and y are each independently 1, 2 or 3;

W is -N(R<sup>1</sup>)C(O)N(R<sup>1</sup>)-;

V is -C(O)-;

J and M are each -C(R<sup>4</sup>)=;

R<sup>1</sup> is selected from the group consisting of hydrogen or C<sub>1</sub>-C<sub>12</sub>alkyl;

each R<sup>4</sup> is independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>9</sup>)<sub>2</sub>;

each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl; and

each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl.

22. The compound of Claim 11 wherein:

x and y are each independently 1, 2 or 3;

W is -O-, -N(R<sup>1</sup>)- or -S(O)<sub>t</sub>- (where t is 0, 1 or 2);

V is -C(O)-;

J and M are each -C(R<sup>4</sup>)=;

R<sup>1</sup> is selected from the group consisting of hydrogen or C<sub>1</sub>-C<sub>12</sub>alkyl;

each R<sup>4</sup> is independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>9</sup>)<sub>2</sub>;

each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl; and

each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl.

23. The compound of Claim 11 wherein:

x and y are each independently 1, 2 or 3;

W is -N(R<sup>1</sup>)S(O)<sub>2</sub>- or -S(O)<sub>2</sub>N(R<sup>1</sup>)-;

V is -C(O)-;

J and M are each -C(R<sup>4</sup>)=;

R<sup>1</sup> is selected from the group consisting of hydrogen or C<sub>1</sub>-C<sub>12</sub>alkyl;

each R<sup>4</sup> is independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>9</sup>)<sub>2</sub>;

each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl; and

each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl.

24. The compound of Claim 11 wherein:

x and y are each independently 1, 2 or 3;

W is -C(O)-;

V is -C(O)-;

J and M are each -C(R<sup>4</sup>)=;

R<sup>1</sup> is selected from the group consisting of hydrogen or C<sub>1</sub>-C<sub>12</sub>alkyl;

each R<sup>4</sup> is independently selected from hydrogen, fluoro, chloro, methyl,

methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>9</sup>)<sub>2</sub>;  
each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl; and  
each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl.

25. The compound of Claim 11 wherein:

x and y are each independently 1, 2 or 3;  
W is -C(O)O- or -N(R<sup>1</sup>)C(O)O-;  
V is -C(O)-;  
J and M are each -C(R<sup>4</sup>)=;  
R<sup>1</sup> is selected from the group consisting of hydrogen or C<sub>1</sub>-C<sub>12</sub>alkyl;  
each R<sup>4</sup> is independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -N(R<sup>9</sup>)<sub>2</sub>;  
each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl; and  
each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl.


26. The compound of any one of Claim 20, Claim 21, Claim 22, Claim 23, Claim 24 and Claim 25 wherein:

x and y are each 1;  
each R<sup>4</sup> is hydrogen; and  
R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> are each hydrogen.

27. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 10.

28. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 10.

## 29. A compound of formula (III):



wherein:

$x$  and  $y$  are each independently 1, 2 or 3;

$W$  is  $-N(R^1)C(O)-$ ,  $-C(O)N(R^1)-$  or  $-OC(O)N(R^1)-$ ;

$G$  and  $M$  are each  $-C(R^4)=$ ;

each  $R^1$  is independently selected from the group consisting of hydrogen,  $C_1-C_{12}$ alkyl,  $C_2-C_{12}$ hydroxyalkyl,  $C_4-C_{12}$ cycloalkylalkyl and  $C_7-C_{19}$ aralkyl;

$R^2$  is selected from the group consisting of  $C_1-C_{12}$ alkyl,  $C_2-C_{12}$ alkenyl,  $C_2-C_{12}$ hydroxyalkyl,  $C_2-C_{12}$ hydroxyalkenyl,  $C_3-C_{12}$ alkoxyalkyl,  $C_3-C_{12}$ cycloalkyl,  $C_4-C_{12}$ cycloalkylalkyl,  $C_7-C_{19}$ aralkyl,  $C_3-C_{12}$  heterocyclyl,  $C_3-C_{12}$ heterocyclylalkyl,  $C_1-C_{12}$ heteroaryl and  $C_3-C_{12}$ heteroarylalkyl;

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

$R^3$  is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy,  $C_1-C_6$ alkyl,  $C_1-C_6$ trihaloalkyl,  $C_1-C_6$ trihaloalkoxy,  $C_1-C_6$ alkylsulfonyl,  $-N(R^{12})_2$ ,  $-OC(O)R^{12}$ ,  $-C(O)OR^{12}$ ,  $-S(O)_2N(R^{12})_2$ , cycloalkyl, heterocyclyl, heteroaryl and heteroarylalkyl, provided that  $R^3$  is not phenyl substituted with optionally substituted thienyl;

each  $R^4$  is independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^9)_2$ ;

each  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$  and  $R^{8a}$  is independently selected from hydrogen or  $C_1-C_3$ alkyl;

or  $R^5$  and  $R^{5a}$  together or  $R^7$  and  $R^{7a}$  together form an oxo group, while the remaining  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$  and  $R^{8a}$  are each independently selected from hydrogen or  $C_1-C_3$ alkyl;

or one of  $R^5$ ,  $R^{5a}$ ,  $R^6$ , and  $R^{6a}$  together with one of  $R^7$ ,  $R^{7a}$ ,  $R^8$  and  $R^{8a}$  form an alkylene bridge, while the remaining  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$ , and  $R^{8a}$  are

each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl; and

each R<sup>12</sup> is independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl,

C<sub>3</sub>-C<sub>6</sub>cycloalkyl, aryl or aralkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

30. The compound of Claim 29 wherein W is -N(R<sup>1</sup>)C(O)-.

31. The compound of Claim 30 wherein:

x and y are each 1;

R<sup>1</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>3</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub> heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, -N(R<sup>12</sup>)<sub>2</sub>, -OC(O)R<sup>12</sup>, -C(O)OR<sup>12</sup>, -S(O)<sub>2</sub>N(R<sup>12</sup>)<sub>2</sub>, cycloalkyl, heterocyclyl, heteroaryl and heteroarylalkyl, provided that R<sup>3</sup> is not phenyl substituted with optionally substituted thiienyl;

each R<sup>4</sup> is hydrogen;

each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is hydrogen; and

each R<sup>12</sup> is independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, aryl or aralkyl.

32. The compound of Claim 31 wherein:

R<sup>2</sup> is independently selected from C<sub>2</sub>-C<sub>12</sub>alkenyl or C<sub>1</sub>-C<sub>12</sub>alkyl optionally substituted by -OR<sup>12</sup>;

R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from the group consisting of halo C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy; and

R<sup>12</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, aryl or aralkyl.

33. The compound of Claim 32 selected from the group consisting of the

following:

4-(2-Trifluoromethyl-benzoyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid  
(3-methyl-butyl)-amide;  
4-(2-Trifluoromethyl-benzoyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid  
(2-phenoxy-ethyl)-amide; and  
4-(2-Trifluoromethyl-benzoyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid  
pentylamide.

34. The compound of Claim 31 wherein:

R<sup>2</sup> is C<sub>7</sub>-C<sub>12</sub>aralkyl optionally substituted by one or more substituents selected from the group consisting of halo, C<sub>1</sub>-C<sub>6</sub>alkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkyl; and  
R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy.


35. The compound of claim 34 selected from the group consisting of the following:

4-(2-Trifluoromethyl-benzoyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid  
phenethyl-amide;  
4-(2-Trifluoromethyl-benzoyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid  
(3-phenyl-propyl)-amide;  
4-(2-Trifluoromethyl-benzoyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid  
[2-(4-fluoro-phenyl)-ethyl]-amide;  
4-(2-Trifluoromethyl-benzoyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid  
[3-(4-fluoro-phenyl)-propyl]-amide; and  
4-(2-Trifluoromethyl-benzoyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid  
[3-(4-fluoro-phenyl)-propyl]-amide.

36. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 29.

37. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 29.

## 38. A compound of formula (IV):



wherein:

x and y are each independently 1, 2 or 3;

W is  $-N(R^1)C(O)-$ ,  $-C(O)N(R^1)-$  or  $-OC(O)N(R^1)-$ ;

G and L are each  $-C(R^4)=$ ;

each  $R^1$  is independently selected from the group consisting of hydrogen,  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl and  $C_7$ - $C_{19}$ aralkyl;

$R^2$  is selected from the group consisting of  $C_1$ - $C_{12}$ alkyl,  $C_2$ - $C_{12}$ alkenyl,  $C_2$ - $C_{12}$ hydroxyalkyl,  $C_2$ - $C_{12}$ hydroxyalkenyl,  $C_3$ - $C_{12}$ alkoxyalkyl,  $C_3$ - $C_{12}$ cycloalkyl,  $C_4$ - $C_{12}$ cycloalkylalkyl,  $C_7$ - $C_{19}$ aralkyl,  $C_3$ - $C_{12}$  heterocyclyl,  $C_3$ - $C_{12}$ heterocyclylalkyl,  $C_1$ - $C_{12}$ heteroaryl and  $C_3$ - $C_{12}$ heteroarylalkyl;

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

$R^3$  is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ trihaloalkyl,  $C_1$ - $C_6$ trihaloalkoxy,  $C_1$ - $C_6$ alkylsulfonyl,  $-N(R^{12})_2$ ,  $-OC(O)R^{12}$ ,  $-C(O)OR^{12}$ ,  $-S(O)_2N(R^{12})_2$ , cycloalkyl, heterocyclyl, heteroaryl and heteroarylalkyl, provided that  $R^3$  is not phenyl substituted with optionally substituted thienyl;

each  $R^4$  is independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^9)_2$ ;

each  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$  and  $R^{8a}$  is independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or  $R^5$  and  $R^{5a}$  together or  $R^7$  and  $R^{7a}$  together form an oxo group, while the remaining  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$  and  $R^{8a}$  are each independently selected from hydrogen or  $C_1$ - $C_3$ alkyl;

or one of  $R^5$ ,  $R^{5a}$ ,  $R^6$ , and  $R^{6a}$  together with one of  $R^7$ ,  $R^{7a}$ ,  $R^8$  and  $R^{8a}$  form an alkylene bridge, while the remaining  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$ , and  $R^{8a}$  are

each independently selected from hydrogen or C<sub>1</sub>-C<sub>3</sub>alkyl;

each R<sup>9</sup> is independently selected from hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl; and

each R<sup>12</sup> is independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl,

C<sub>3</sub>-C<sub>6</sub>cycloalkyl, aryl or aralkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

39. The compound of Claim 38 wherein W is -N(R<sup>1</sup>)C(O)-.

40. The compound of Claim 39 wherein:

x and y are each 1;

R<sup>1</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>3</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub> heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, -N(R<sup>12</sup>)<sub>2</sub>, -OC(O)R<sup>12</sup>, -C(O)OR<sup>12</sup>, -S(O)<sub>2</sub>N(R<sup>12</sup>)<sub>2</sub>, cycloalkyl, heterocyclyl, heteroaryl and heteroarylalkyl, provided that R<sup>3</sup> is not phenyl substituted with optionally substituted thiienyl;

each R<sup>4</sup> is independently selected from hydrogen, fluoro, chloro, methyl, methoxy or trifluoromethyl;

each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is hydrogen; and

each R<sup>12</sup> is independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, aryl or aralkyl.

41. The compound of Claim 40 wherein:

R<sup>2</sup> is independently selected from C<sub>2</sub>-C<sub>12</sub>alkenyl or C<sub>1</sub>-C<sub>12</sub>alkyl;

R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from the group consisting of halo C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl and C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy; and

R<sup>12</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, aryl or aralkyl.

42. The compound of Claim 41 selected from the group consisting of the

following:

4-trifluoromethyl-2-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]- pyrimidine-5-carboxylic acid (3-methylbutyl)amide; and

2-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]pyrimidine-5-carboxylic acid (3-methylbutyl)amide.

43. The compound of Claim 40 wherein:


$R^2$  is  $C_7-C_{12}$ aralkyl optionally substituted by one or more substituents selected from the group consisting of halo,  $C_1-C_6$ alkyl and  $C_1-C_6$ trihaloalkyl; and

$R^3$  is phenyl optionally substituted by one or more substituents selected from the group consisting of halo,  $C_1-C_6$ alkyl,  $C_1-C_6$ trihaloalkyl and  $C_1-C_6$ trihaloalkoxy.

44. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 38.

45. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 38.

46. A compound of formula (Ia):



wherein:

$x$  and  $y$  are each independently 1, 2 or 3;

$W$  is  $-N(R^1)C(O)N(R^1)-$ ,  $-O-$ ,  $-N(R^1)-$ ,  $-S(O)_t-$  (where  $t$  is 0, 1 or 2),  $-N(R^1)S(O)_2-$ ,  $-S(O)_2N(R^1)-$ ,  $-C(O)O-$  or  $-N(R^1)C(O)O-$ ;

$V$  is  $-C(O)-$ ,  $-C(O)O-$ ,  $-C(S)-$ ,  $-C(O)N(R^1)-$ ,  $-S(O)_2-$  or  $-S(O)_2N(R^1)-$ ;

$G$ ,  $J$ ,  $L$  and  $M$  are each independently selected from  $-N=$  or  $-C(R^4)=$ ; provided that at least two of  $G$ ,  $J$ ,  $L$  and  $M$  are  $-N=$ , and provided that when  $G$  and  $J$

are both  $-C(R^4)=$ ; L and M can not both be  $-N=$ , and when L and M are both  $-C(R^4)=$ , G and J can not both be  $-N=$ ;

each  $R^1$  is independently selected from the group consisting of hydrogen,  $C_1-C_{12}$ alkyl,  $C_2-C_{12}$ hydroxyalkyl,  $C_4-C_{12}$ cycloalkylalkyl and  $C_7-C_{19}$ aralkyl;

$R^2$  is selected from the group consisting of  $C_1-C_{12}$ alkyl,  $C_2-C_{12}$ alkenyl,  $C_2-C_{12}$ hydroxyalkyl,  $C_2-C_{12}$ hydroxyalkenyl,  $C_2-C_{12}$ alkoxyalkyl,  $C_3-C_{12}$ cycloalkyl,  $C_4-C_{12}$ cycloalkylalkyl, aryl,  $C_7-C_{19}$ aralkyl,  $C_3-C_{12}$ heterocyclyl,  $C_3-C_{12}$ heterocyclylalkyl,  $C_1-C_{12}$ heteroaryl, and  $C_3-C_{12}$ heteroarylalkyl;

or  $R^2$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

$R^3$  is selected from the group consisting of  $C_1-C_{12}$ alkyl,  $C_2-C_{12}$ alkenyl,  $C_2-C_{12}$ hydroxyalkyl,  $C_2-C_{12}$ hydroxyalkenyl,  $C_2-C_{12}$ alkoxyalkyl,  $C_3-C_{12}$ cycloalkyl,  $C_4-C_{12}$ cycloalkylalkyl, aryl,  $C_7-C_{19}$ aralkyl,  $C_3-C_{12}$ heterocyclyl,  $C_3-C_{12}$ heterocyclylalkyl,  $C_1-C_{12}$ heteroaryl and  $C_3-C_{12}$ heteroarylalkyl;

or  $R^3$  is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

each  $R^4$  is independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or  $-N(R^9)_2$ ;

each  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$  and  $R^{8a}$  is independently selected from hydrogen or  $C_1-C_3$ alkyl;

or  $R^5$  and  $R^{5a}$  together, or  $R^6$  and  $R^{6a}$  together, or  $R^7$  and  $R^{7a}$  together, or  $R^8$  and  $R^{8a}$  together are an oxo group, provided that when V is  $-C(O)-$ ,  $R^6$  and  $R^{6a}$  together or  $R^8$  and  $R^{8a}$  together do not form an oxo group, while the remaining  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$  and  $R^{8a}$  are each independently selected from hydrogen or  $C_1-C_3$ alkyl;

or one of  $R^5$ ,  $R^{5a}$ ,  $R^6$ , and  $R^{6a}$  together with one of  $R^7$ ,  $R^{7a}$ ,  $R^8$  and  $R^{8a}$  form an alkylene bridge, while the remaining  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6a}$ ,  $R^7$ ,  $R^{7a}$ ,  $R^8$ , and  $R^{8a}$  are each independently selected from hydrogen or  $C_1-C_3$ alkyl; and

each  $R^9$  is independently selected from hydrogen or  $C_1-C_6$ alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

47. The compound of Claim 46 wherein W is -N(R<sup>1</sup>)C(O)N(R<sup>1</sup>)- and V is -C(O)-.

48. The compound of Claim 47 wherein:

x and y are each 1;

each R<sup>1</sup> is independently selected from the group consisting of hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl;

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>2</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl, and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>3</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>12</sub>hydroxyalkenyl, C<sub>2</sub>-C<sub>12</sub>alkoxyalkyl, C<sub>3</sub>-C<sub>12</sub>cycloalkyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, aryl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl, C<sub>1</sub>-C<sub>12</sub>heteroaryl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

each R<sup>4</sup> is hydrogen; and

each R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>7</sup>, R<sup>7a</sup>, R<sup>8</sup> and R<sup>8a</sup> is hydrogen.

49. The compound of Claim 48 wherein:

R<sup>2</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>4</sub>-C<sub>12</sub>cycloalkylalkyl, C<sub>7</sub>-C<sub>19</sub>aralkyl, C<sub>3</sub>-C<sub>12</sub>heterocyclylalkyl and C<sub>3</sub>-C<sub>12</sub>heteroarylalkyl;

R<sup>3</sup> is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkyl, C<sub>1</sub>-C<sub>6</sub>trihaloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, -N(R<sup>12</sup>)<sub>2</sub>, -OC(O)R<sup>12</sup>, -C(O)OR<sup>12</sup>, -S(O)<sub>2</sub>N(R<sup>12</sup>)<sub>2</sub>, cycloalkyl, heterocyclyl, heteroaryl and heteroarylalkyl; and

each R<sup>12</sup> is independently selected from hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>3</sub>-C<sub>6</sub>cycloalkyl, aryl or aralkyl.

50. A method of treating a disease or condition mediated by stearoyl-CoA desaturase (SCD) in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 46.

51. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 46